Last reviewed · How we verify
Combination of DMARDs
A combination of disease-modifying antirheumatic drugs (DMARDs) that work synergistically to suppress immune-mediated inflammation and slow progression of rheumatic disease.
A combination of disease-modifying antirheumatic drugs (DMARDs) that work synergistically to suppress immune-mediated inflammation and slow progression of rheumatic disease. Used for Rheumatoid arthritis, Other inflammatory arthropathies.
At a glance
| Generic name | Combination of DMARDs |
|---|---|
| Also known as | MTX: Trexan or Methotrexate, SSZ: Salazopyrin, HCQ: Oxiklorin |
| Sponsor | Helsinki University Central Hospital |
| Drug class | Disease-modifying antirheumatic drug (DMARD) combination |
| Modality | Small molecule |
| Therapeutic area | Immunology / Rheumatology |
| Phase | Phase 3 |
Mechanism of action
DMARD combinations typically include agents such as methotrexate, sulfasalazine, and hydroxychloroquine, or biologic DMARDs targeting specific immune pathways (TNF inhibitors, IL-6 inhibitors, JAK inhibitors). When used together, they provide complementary immunosuppressive effects that reduce joint inflammation, prevent bone and cartilage damage, and improve clinical outcomes more effectively than monotherapy.
Approved indications
- Rheumatoid arthritis
- Other inflammatory arthropathies
Common side effects
- Infection (including serious infections)
- Hepatotoxicity
- Bone marrow suppression
- Gastrointestinal disturbance
- Elevated liver enzymes
Key clinical trials
- IL6-receptor Inhibitor Iwith Belumosudil for the Treatment of Belumosudil-refractory cGVHD (PHASE1)
- Analysis of T and B Cell Repertoire Changes in Response to Orencia® (Abatacept) in Rheumatoid Arthritis
- Severe Psoriatic Arthritis - Early intervEntion to Control Disease: the SPEED Trial (PHASE4)
- A Study of Iguratimod in Combination With Tofacitinib in RA Patients (PHASE4)
- Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic (cs)/Biologic (b) Disease Modifying Anti-rheumatic Drugs (DMARDs) (PHASE3)
- An Efficacy and Safety Study of Subcutaneous Tocilizumab in Combination With Methotrexate (MTX) and as Monotherapy Versus MTX in Participants With Moderate to Severe Rheumatoid Arthritis With Inadequate Response to Current Disease-Modifying Antirheumatic Drug (DMARD) Therapy (PHASE3)
- Immunosuppressant Combined With Pirfenidone in CTD-ILD (PHASE4)
- Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) Inhibitors (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Combination of DMARDs CI brief — competitive landscape report
- Combination of DMARDs updates RSS · CI watch RSS
- Helsinki University Central Hospital portfolio CI